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Introduction 
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Cancer is a disease brought on by a combination of causal and predisposing 
genetic factors and which at a given moment and under favorable conditions may 
take effect in predisposed people
1
. Squamous cell carcinoma is the most common 
cancer of the oral cavity. It is a major health problem worldwide affecting patients 
older than 50 years of age. However, several recent studies show that there is an 
increasing incidence among people younger than 40 years of age. 
2-5
 
 Oral squamous cell carcinoma (OSCC) in males is the sixth most common 
cancer after lung, prostate, colorectal, stomach and bladder cancer. In females, it is 
the tenth most common site of cancer after breast, colorectal, lung, stomach, uterus, 
bladder and liver 
6
. Major risks factors for OSCC include tobacco, areca nut in 
various forms and alcohol consumption. Despite considerable advancements in 
diagnosis, treatment and our understanding of the molecular mechanisms of this 
malignancy, the high morbidity rate and the five-year survival rate for head and neck 
squamous cell carcinoma (HNSCC) have not improved in the past two decades 
7
. 
 Metastasis is the hallmark of malignancy that can occurs via blood vessels 
(hematogenous spread), lymphatics (lymphogenous spread) or by invasion of body 
cavities such as the pleura or peritoneum( transcoelomic). Neoangiogenesis 
facilitates invasion and metastasis, as it is an essential process in progression of 
malignant tumors, due to the fact that solid tumors cannot grow beyond 1-2 mm 
without neovascularisation
8
. 
 Neoangiogenesis is the formation of new blood vessels in post natal life and is 
an essential step for many physiological process such as growth, wound healing and 
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organ regeneration. One of the main differences between the normal and 
pathological angiogenesis is that in the latter, the vessels are highly disorganized and 
their walls have many openings leading to leaky vessels. Neoangiogenesis, 
lymphatic dissemination and local recurrence are the main factors influencing 
progression of head and neck squamous cell carcinoma.
9
 
  The small microvessels in most of the tumors are not only the source of 
oxygen and nutrition but also the key element of hematogenous dissemination. 
Tumor growth is critically associated with the vascularization of tumor tissue. 
Vascular endothelial growth factor and interleukin-8 are promoters of angiogenesis, 
and they are over expressed in OSCC. Therapeutic modalities also affect the 
vascularity and such changes may have prognostic and predictive significance.
10
 
 CD34 is a heavily glycosylated type I transmembrane molecule  expressed on 
small vessel endothelial cells
11-13
 and tumors of epithelial origin 
14,15
. It is expressed 
on developmentally early lympho-hematopoietic stem cells and progenitor cells, 
small vessel endothelial cells and embryonic fibroblasts. It is a marker of 
hematopoietic stem cell and the monoclonal antibody CD 34 recognizes a cell 
surface antigen of approximately 110 KD that is selectively expressed on human 
hematopoietic progenitor cells. This unique specificity facilitates staining of 
vascular endothelial cell.
15
 
 The present study was done to assess vascular pattern immunohistochemically 
using antibody to CD34  which is an endothelial cell membrane marker, in paraffin 
embedded tissue sections of OSCC.  
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Aims and Objectives 
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Aim and Objectives 
 
 To evaluate CD 34 expression in formalin fixed paraffin embedded tissues of 
metastatic oral squamous cell carcinoma by immunohistochemistry. 
 To evaluate CD 34 expression in formalin fixed paraffin embedded tissue of 
“non-metastatic” oral squamous cell carcinoma by immunohistochemistry 
 To evaluate CD 34 expression in formalin fixed paraffin embedded tissue of 
normal buccal mucosa by immunohistochemistry 
 To compare CD 34 expression in metastasizing oral squamous cell 
carcinoma, non metastasizing oral squamous cell carcinoma and normal 
buccal mucosa. 
 
Hypothesis (Null) 
There is no change in CD 34 expression in metastasizing oral squamous cell 
carcinoma, non metastasizing oral squamous cell carcinoma and normal buccal 
mucosa. 
Hypothesis (Alternate) 
There is a change in CD 34 expression in metastasizing oral squamous cell 
carcinoma, non metastasizing oral squamous cell carcinoma and normal buccal 
mucosa. 
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Materials and Methods  
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Study setting 
The study was conducted in Department of Oral and Maxillofacial 
Pathology, Ragas Dental College and Hospital, Chennai, using archival formalin 
fixed paraffin embedded tissues. 
A retrospective study was done to evaluate the expression of CD 34 in 
metastasizing oral squamous cell carcinoma, non metastasizing oral squamous cell 
carcinoma and normal buccal mucosa using immunohistochemistry in archival 
tissue specimens. 
Study sample size 
The study material comprised of 35 formalin fixed, paraffin embedded tissue 
specimens (archival blocks). 
1. 10 histopathologically confirmed oral squamous cell carcinoma tissue 
specimens with metastasis       
2.  15 histopathologically confirmed oral squamous cell carcinoma tissue 
 specimens.  
3.  10 normal buccal mucosa tissues specimens. 
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Group 1           
Archival blocks of 10 patients of oral squamous cell carcinoma that had 
metastasized to the regional lymph nodes of neck confirmed by histopathology were 
selected. 
Group 2 
 Archival blocks of 15 patients of oral squamous cell carcinoma that had not 
metastasized, confirmed histopathologically, were selected. 
Group 3 
 Archival blocks of 10 cases of clinically normal buccal mucosa which were 
taken from buccal mucosa adjacent to impacted lower third molar region obtained 
after patient consent. 
Methodology 
 This study was approved by Institutional Review Board (IRB) of Ragas 
Dental College and Hospital, Chennai and patient consent was taken for normal 
controls (Annexure1). 
Five micron thick sections were cut from the paraffin embedded blocks and 
used for routine hematoxylin and eosin (H & E) staining and immunohistochemical             
(IHC) staining. 
13 
 
HEMATOXYLIN & EOSIN STAINING 
 
Reagents 
 
 Harris’s hematoxylin 
 1% acid alcohol 
 Eosin 
Procedure 
 The slides were dewaxed in xylene and hydrated through graded alcohol to 
 water. 
 The sections on the slides were flooded with Harris’s hematoxylin for 5 
 minutes. 
 The slides were washed in running tap water for 5 minutes. 
 The slides were differentiated in 1% acid alcohol for 30 seconds. 
 The slides were washed well in running tap water for 5 minutes. 
 The tissue sections on the slides were then stained in eosin for 30 seconds. 
 The slides were washed in running tap water for 1 minute. 
 The slides were then dehydrated through alcohol, cleared, mounted with DPX 
 and viewed under the light microscope(LM). 
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IMMUNOHISTOCHEMISTRY (IHC) 
Armamentarium (Fig. 1) 
 Microtome 
 Autoclave 
 Hot air oven 
 Coplin jars 
 Measuring jar 
 Weighing machine 
 APES coated slides 
 Slide carrier 
 Aluminium foil 
 Micro-pipettes 
 Toothed forceps 
 Electronic timer 
 Beakers 
 Rectangular steel tray with glass rods 
 Sterile gauze 
 Cover-slips 
 Light microscope 
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Reagents used 
1.   Concentrated HCl 
2.   Laxbro soln 
3.   APES (3 amino propyl tri ethoxy silane) 
4.   Acetone 
5.  1N sodium hydroxide 
6.  1N Hcl 
7.   Citrate buffer 
8.   Phosphate Buffered Saline (PBS) 
9.   3% H2O2 
10.  Deionized water 
11.  Distilled water 
12.  Hematoxylin 
13.  Absolute alcohol (Isopropyl alcohol) 
14.  Xylene 
Antibodies used (Fig. 2) 
1.  Primary antibody – Anti CD 34  mouse monoclonal antibody 
2.  Secondary antibody –  Poly horseradish peroxidase 
3.  Chromogen – DAB-3,3’- diamino-benzidine tetrahydrochloride 
The antibodies and the chromogen used were from the Biogenix
TM
 company. 
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IHC Procedure 
Pretreatment of the slides 
 The slides were first washed in tap water for few minutes 
 The slides were then soaked in detergent solution for 1 hour 
 After 1 hour, each slide was brushed individually using the detergent solution 
and were transferred to distilled water. 
 The slides were washed in two changes of distilled water. 
 The slides were washed in autoclaved distilled water. 
 The slides were immersed in 1 N HCL (100 ml HCl in 900 ml distilled water)     
overnight. 
 The following day slides were taken out of acid and washed in two changes of 
autoclaved distilled water. 
 All the slides were then transferred to slide trays, wrapped in aluminium foil and 
baked in hot air oven for 4 hours at 180 degrees centigrade. 
 
APES (3 Amino propyl tri ethoxy silane) coating 
Slides first dipped in coplin jar containing acetone for 2 minutes 
Dipped in APES for 5 minutes 
Dipped in two changes of distilled water for 2 minutes each 
Slides left to dry 
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Preparation of paraffin sections 
After the slides were dry, tissue section of 5 micron thickness were made in a 
rotary manual microtome. The ribbons of tissue section were transferred onto the 
APES coated slide from the tissue float bath such that two tissue bits come on to the 
slide with a gap in between. One of the tissue sections towards the frosted end of the 
slide was labeled positive (P) to which the primary antibody, secondary antibody 
and chromogen were added, the tissue section away from frosted side is the negative 
(N) to which negative serum, the secondary and the chromogen were added. 
IHC Procedure 
The slides with tissue sections were treated with three changes of xylene to 
remove paraffin wax. They were put in descending grades of alcohol and then 
rehydrated with water. Circles were drawn using a diamond marker around the 
tissues, so that the antibodies added later on do not spread and are restricted to the 
circle.  
The slides were transferred to citrate buffer of pH 6 and autoclaved for 
antigen retrieval at 15 lbs pressure for 30 minutes. Slides were then treated with 3% 
hydrogen peroxide for 30 minutes to quench endogenous peroxidase activity of cells 
that would otherwise result in non – specific staining then the slides were dipped in 
3 changes of aqueous deionised water for 5 minutes each. The tissues were 
incubated in protein blocking serum for 10 min in an enclosed humidified chamber. 
Then the slides were wiped carefully without touching the tissue section to remove 
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excess of blocking serum. The pre diluted primary antibody, CD 34 was added to P 
tissue on the slide and then to the N tissue negative reagent was added. The slides 
were incubated for one hour. Then the slides were wiped carefully without touching 
the tissue section to remove excess of antibody and washed with three changes of 
cold PBS for 5 minutes. Then super enhancer reagent is added and incubated for 20 
min. Then the slides were wiped carefully without touching the tissue section to 
remove excess of enhancer and washed with three changes of cold PBS for 5 
minutes .Then a drop of poly horseradish peroxidase was added on both the sections 
and the slides were incubated for 30 minutes.  Later slides were washed in three 
changes of cold PBS for 5 minutes in each. The slides were wiped carefully without 
touching the tissue section to remove excess PBS. Then a drop of DAB was added to 
the sections and incubated for 15 min. Slides were then washed in deionised water to 
remove excess chromogen and counter stained with hematoxylin. Then the slides 
were transferred to 70% alcohol, 100% alcohol and one change of xylene. The tissue 
sections were mounted with DPX.  
The slides were then observed under the microscope. Throughout the 
procedure care was taken not to dry the tissues. 
Positive Control 
A case of metastasizing oral squamous cell carcinoma tissue specimen 
known to express CD 34 positive cells were fixed, processed, embedded, sectioned, 
stained in same manner and used as positive control. One positive control tissue 
slide was included for each batch of staining. The tissue section away from the 
frosted end of the slide was taken as the negative control. 
19 
 
IHC PROCEDURE FLOW CHART 
APES coated slides with 2 paraffin embedded tissue 
Placed in xylene thrice (5 minutes each) 
Placed in 100% isopropanol (5 minutes) 
Placed in 70% isopropanol (5 minutes) 
Washed in distilled water thrice (5 minutes each) 
kept in citrate buffer at pH 6 and autoclaved for antigen retrieval and bench cooled 
for 40 minutes 
Placed in 3% hydrogen peroxide  (20 min) 
 
Protein blocking serum added and incubated for 10 minutes 
Primary antibody added and incubated for one hour 
Washed in PBS thrice (5 minutes each) 
Super enhancer reagent added and incubated for 20 minutes 
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Secondary antibody added and incubated in an enclosed hydrated container  
(30 minutes) 
Washed in PBS thrice (5 minutes each) 
DAB added and incubated in an enclosed in hydrated container (15 minutes) 
Washed in PBS thrice (5 minutes each) 
Stained with hematoxylin(20 seconds) 
Washed in tap water 
Placed in 70% isopropanol (1 minute) 
Placed in 90% isopropanol (1 minute) 
Placed in 100% isopropanol (1 minute) 
Placed in xylene (1 dip) 
Slides were mounted using DPX 
Slides were observed under the LM and graded 
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Criteria for evaluation of CD 34 staining 
The following parameters were used to evaluate CD 34 staining 
1. Tissue localization of stain : CD 34 staining is localized to cell membranes 
of the endothelium of blood vessels 
2. Degree of positivity : The number of vessels were counted under 10x 
objective. The number of vessels were counted throughout the section and 
divided by the number of grids counted. Each positive case was graded as no 
stain: (0), mild (+) : fewer than 10 positive blood vessels/mm
2
, moderate 
(++) : 10- 20 positive blood vessels/mm
2
 , and severe (+++) : more than 20 
positive blood vessels/mm
2
.
16
 
 
Statistical analysis was done using SPSS 
TM 
software (version 11.5). Mann -
Whitney U test. Chi-square test was done to find the association of intensity between 
metastasizing and non metastasizing oral squamous cell carcinoma. Mann-Whitney 
U test was done to compare the number of CD 34 positive vessels between 
metastasizing and non metastasizing oral squamous cell carcinoma.  
Kruskal- Wallis test was done to compare the number of CD 34 positive 
vessels per unit area of the tissue section among all three group namely, normal, 
nonmetastasizing and metastasizing oral squamous cell carcinoma. 
 p <  0.05 was considered to be statistically significant. 
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CANCER EPIDEMIOLOGY 
Head and neck squamous cell carcinoma (HNSCC) ranks eighth worldwide 
for cancer-related mortality, with an estimated 378,500 new cases of intraoral cancer 
diagnosed annually.
17
According to estimates from the International Agency for 
Research on Cancer (IARC), there were 10.6% new cancer cases and 9.7% mortality 
in 2008 worldwide. In India, the incidence rate and mortality rate in 2008 were 4.7% 
and 5.3% respectively
18
. Oral squamous cell carcinoma (OSCC) in males in Chennai 
during 2006-08 was the third most common cancer after lung and stomach cancer. 
While in females it was found to be the fourth most common site of cancer after 
breast, cervix and ovary. Cancer of the oral cavity during 2006-08 in Chennai for 
males (8.9%) ranked 3
rd
 and for females (5.8%) ranked 4
th
 among the other cancers.
6
 
In India Bhopal ranks the highest for oral cancer (10.2%) followed by Mumbai 
(7.9%) Delhi (6.8%), Chennai (6.4%), among all cancers
19
. 
The peak incidence of oral cancer occurred in the age group of 65-69 years 
among men and 70-74 years among women. Among males, lung cancer was ranked 
at the top followed by stomach, oral cavity, oesophagus and oropharynx and among 
the females cancer of the breast was the most common followed by cervix, ovary, 
oral cavity and stomach during 2006-08.
 
Buccal mucosa (55%) accounted for the 
majority of oral cancers followed by alveolus (14%); unspecified oral cancer 
constituted 13% out of which 88% was squamous cell carcinoma histologically. 
Cancer of the tongue was ranked within the top ten cancers among men but not 
among women during 2006-2008 in Bhopal in India
20
. 
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Anterior tongue constituted 42% while posterior or base tongue accounted 
for 27% and 91% were histologically squamous cell carcinoma. Cancer of the oral 
cavity was ranked fourth among men and fifth among women during 2006-2008.The 
distribution of cases by individual sites and subsites were the following: Among 
males, cheek mucosa (38%) was the commonest followed by anterior 2/3 tongue 
(31%), gum (9%) and floor of mouth (8%). Among females, the order was cheek 
mucosa (43%), anterior 2/3 tongue (27%), gum (12%), hard palate and lip (4%), 
floor of mouth (2%) of which 89% was squamous cell carcinoma histologically.
6
 
AETIOLOGY 
Major risks factors include the use of tobacco, areca nut in various forms and 
alcohol consumption. It has long been recognized that there is a strong association 
between heavy alcohol use and cigarette smoking. Approximately 80% of alcohol 
dependent patients are reported to smoke cigarettes
20
. Dependence on nicotine 
appears more in smokers with habit of alcohol consumption
21
. Simultaneous use of 
tobacco and alcohol contributes to an increased incidence of several malignancies, 
especially head and neck cancers. Men who smoke and drink are nearly 38 times 
more likely to develop head and neck cancers than men who have neither of the 
habits.
22
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FIG 1 : DISTRIBUTION OF CAUSATIVE RISK FACTORS  
FOR ORAL CANCER 
 
The main disorders that may precede the development of oral cancer (WHO 
experts working group) are: leukoplakia, erythroplakia, palatal lesion of reverse 
cigar smoking, oral lichen planus, oral submucous fibrosis, discoid lupus 
erythematosus, hereditary disorders such as dyskeratosis congenital and 
epidermolysis bullosa 
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CLINICAL FEATURE 
The most common site of occurrence of oral squamous cell carcinoma is the 
buccal mucosa, lateral part of the tongue, alveolar mucosa, and floor of the mouth 
followed by lower lip and palate. Cancer of upper lip is very rare.
6 
The most 
common clinical presentation is that of an ulcerated exophytic lesion and duration 
90%
75%
20%
30%
tobacco
alcohol
UV light
HPV
source:ncrp.org
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ranging from few weeks to several months.
24 
Early carcinoma may be asymptomatic 
initially and later may present as an indolent ulcer which fails to heal, differentiating 
it from other types of ulcers which heals after few weeks.  
The early asymptomatic lesion may exhibit erythroplakic changes which are 
smooth or granular in texture without induration. Symptomatic lesions may show 
areas of induration surrounded by leukoplakic changes. Specific premalignant lesion 
such as a white patch (leukoplakia) or red patch (erythroplakia) may exist before 
frank malignancy. 
Predictor factors for oral cancer and its potential for malignant disorders 
25
 
Predictive factors Potential for malignant disorders 
Age and duration The first five years of oral lesion is the most 
critical period for the malignancy development. 
The older the patient the worse is the prognosis. 
Site Lateral border of tongue and floor of mouth are 
the most critical sites for malignant 
transformation. 
Tongue carcinoma is more aggressive than 
carcinoma of any other oral site. 
Size Multiple oral ulcers have four times more 
chances to become malignant than single 
anatomical lesion. 
Gender and clinical Appearance Several studies point out a propensity of 
leukoplakia in female to become malignant when 
compared to male. 
Lesions containing nodular and red areas have 
been shown to be a greater risk of 
Malignant transformation than the uniform ones. 
27 
 
PROGNOSTIC FACTORS 
 The five year survival rate of head and neck squamous cell carcinoma 
(HNSCC) is less than 50% in the last two decades even though there is considerable 
improvements in diagnosis, treatment and understanding of the molecular 
mechanisms of this malignancy.
26
81% of patients with OSCC survive for at least 
one year after diagnosis and the five-year relative survival rate for all stages of the 
disease is approximately 50 percent,
27 
which has not changed significantly in the last 
few decades.
28,29
 
The following survival statistics is from the National Cancer Institute's SEER 
program (2001)
8
 
Site of cancer Five year survival rate 
 Stage 1 Stage II Stage III Stage IV 
Tongue 71% 59% 47% 37% 
lip 96% 83% 57% 48% 
Floor of mouth 73% 60% 36% 30% 
Alveolus 81% 62% 45% 40% 
Oropharynx and tonsil 56% 58% 55% 44% 
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Stage Distribution and 5-year Relative Survival by Stage at Diagnosis  
from the National Cancer Institute's SEER program 2004-2008
8
 
Stage at diagnosis  5 year survival rate (%) 
Localized (confined to primary site) 82.4 
Regional (spread to regional lymph node) 55.5 
Distant (cancer has metastasized) 32.2 
Unknown (unstaged) 50.4 
 
For early-stage OSCC (stage I and II [before regional or distant spread 
occurs]), the five-year survival rate is approximately 80%, whereas in advanced-
stage disease (stage III and IVa), the five-year survival rate is less than 25% .
30-33
 
Advanced disease requires more aggressive therapy involving combined modalities 
that result in significant morbidity and a negative impact on patients’ quality of life, 
as well as a high cost of care.  
This poor outcome is related primarily due to late stage of diagnosis, high 
degree of local invasion into surrounding tissue and a high incidence of metastasis to 
cervical lymph nodes. This low survival rate may be due in part to the highly 
vascularized and immune suppressive nature of these tumors. It is necessary to 
understand the molecular mechanism of oral cancer progression to find a prognostic 
indicator for early diagnosis and management.
34
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METASTASIS 
Metastasis is the hallmark of malignancy, the most deadly aspect of tumor is 
its ability to spread or metastasize. The process of metastasis consists of sequential 
steps including proliferation, induction of angiogenesis, detachment, motility, 
invasion into circulation, aggregation and survival in the circulation, cell arrest in 
distant capillary beds, finally, extravasation into parenchyma of an organ or tissue.  
Cancer cells initially group together to form a primary tumor. Once the 
tumor is formed, cells may begin to break off from this tumor and travel to other 
parts of the body, this process is metastasis. Cells from malignant primary tumors 
spread from their sites of origin to invade local tissue and enter the systemic 
/lymphatic circulation.
35
This spread can occur directly into the local tissue or via 
blood vessels (hematogenous spread) and lymphatics (lymphogenous spread) or by 
invasion of body cavities such as the pleura or peritoneum. To metastasize, a tumor 
cell must break away from its tumor, invade either the circulatory or lymph system, 
which will carry it to a new location and establish itself in the new site. The body 
has many safeguards to prevent cells from doing this, yet many cancer cells have the 
ability to overcome these safeguards. Tumor cells can spread around the body using 
one of two major “highways”, vascular and lymphatic system.35 
All tissues are supplied by blood vessels (which provide oxygen and 
nutrients) and also lymphatic vessels which drain excess fluid to nearby lymph 
glands. For many cancer cells, their first opportunity to escape is to use the 
lymphatic drainage system. This is the reason why for many cancers, lymph nodes 
30 
 
are biopsied or removed at surgery to see if the cancer has spread. Cancer cells can 
enter the bloodstream either indirectly via the lymphatics, or directly from a vessel 
in the primary tumour. The bloodstream is a very harsh environment with a high 
velocity of flow and protective immune cells. Moreover, cancer cells also attach to 
the proteinaceous matrix, many tumour cells die when detached from their support 
and some have to swim. The majority of tumour cells get arrested in the first 
capillary bed that they float into vessel lumen.
35
 
About 100 years ago, a British pathologist named Dr. Stephen Paget 
described metastasis by a “Seed and Soil” hypothesis. The development of a 
metastasis involves three major steps (1) Invasion: cells of the primary tumor 
migrate into surrounding tissues and penetrate the walls of blood vessels. (2) 
Embolism: Tumor cells break loose within the vessels and are carried to distant 
parts; the cells are arrested in capillaries or arterioles. (3) Development of arrested 
emboli: Cells of the arrested embolus multiply, invade the vessel wall, and infiltrate 
adjacent tissues. Simultaneously, a vascularized stroma grows from the local tissues 
and supports growth of the tumor cells. Thus, a new tumor forms in a distant site 
resulting in metastasis.
36
 
Invasion is the initiating factor for tumour metastasis, without which tumour 
cells cannot metastasize. Cancer cells lack intercellular adhesion due to deficient 
calcium; hence cells are attached loosely with each other and can easily separate. 
The separated cells migrate to the surrounding tissue by their own active ameboid 
movement.
36
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In the course of their invasion, tumor cells penetrate blood vessels, veins are 
more commonly invaded as their walls are readily permeable and rarely arteries, 
since arterial walls are thicker acting as a barrier. Within the vessel, cancer cells may 
be swept away in the venous stream, or they may adhere locally and multiply.  
Thrombus forms around the tumor cells and pieces of the thrombus may 
break off and laden with malignant cells, be carried to and lodge in distant organs. 
Tumor cell emboli usually lodge in the small vessels of an organ. Development of 
the emboli into metastasis occurs by multiplication of tumor cells which then invade 
into the vessel wall and neighboring parenchyma by concurrent ingrowth of 
vascularized stroma from the local tissues.
36
 
 Albo et al. found that tumor angiogenesis in human head and neck 
squamous cell carcinoma was directly related to clinical outcome including early 
and extensive recurrence or metastasis.
37
 William et al reported that tumor 
angiogenesis in oral cavity showed a strong correlation with regional recurrence
38
. 
In addition, Lopez-Graniel et al observed significant correlations between MVD 
(micro vascular density) and recurrence of the tumor, lymph node metastases and 
tumor size among patients with oral squamous cell carcinoma.
39
 
ANGIOGENESIS 
Angiogenesis refers to formation of new micro-vessels. Tumor 
neoangiogenesis occurs by recruitment of endothelial cell precursor or by sprouting 
of existing capillaries as in physiologic angiogenesis. However, tumor blood vessels 
32 
 
differ from the normal vasculature by having altered morphology that favours 
metastasis. Neoangiogenesis is a complex process that involves multiple steps: 
remodelling of the extracellular matrix, proliferation and migration of endothelial 
cells, differentiation into capillaries, anastomosis, and finally formation of the 
vascular lumen.
9 
These processes result in growth of new blood vessels into areas of 
hypoxic cells.  
Tumor growth depends on angiogenesis and the ingrowth of new capillaries 
increases the opportunity for tumor cells to enter the circulation and metastasize to a 
distant site.
40, 41
The most essential component of blood vessels is the endothelial cell 
(EC). The formation of blood vessels can be divided into two separate processes. 
Vasculogenesis is the “in situ” differentiation of endothelial cells from 
haemangioblasts (precursors of EC) and their subsequent organisation into a 
primitive vascular network.  
Angiogenesis is the sprouting, splitting and remodelling of existing vessels. 
Vasculogenesis is confined to early embryonic development and is responsible for 
the formation of the primary vasculature, including the main vessels of the heart and 
lungs. Angiogenesis subsequently extends the circulation into previously avascular 
regions by the controlled migration and proliferation of EC. As in other cancers, 
angiogenesis has been also been implicated in the progression of squamous cell 
carcinomas of the head and neck .
42, 43
 
Angiogenesis and tumor progression are very closely linked with each other. 
Tumor cells are dependent on angiogenesis because their growth and expansion 
33 
 
require oxygen and nutrients, which are made available through the angiogenic 
vasculature. Investigational studies on tumor development have shown that an 
alteration in the blood supply can noticeably affect the tumor growth and its 
metastasis. Different cells and stimulating factors are involved in angiogenesis. 
Some of the cells engaged are the endothelial cells (EC), lymphocytes, macrophages 
and mast cells. Vascular endothelial growth factor (VEGF) and fibroblast growth 
factor (FGF) are two of the major ones among the many factors involved in this 
process. These cells and stimulating factors play different and important role during 
tumor angiogenesis.
44
 
The process of angiogenesis includes two major phases, namely the 
activation phase and the formation phase. Tumor cells require nutrients and oxygen 
to overcome hypoxia and starvation. When a condition such as hypoxia is present in 
the tumor tissue, the tumor cells receive the signal and promote the angiogenic 
switch and induce angiogenesis. In the case of hypoxia, the signal is mediated by 
hypoxia inducible factor-1 (HIF-1).HIF-1 binds to hypoxia-response elements 
(HREs) and activates a number of hypoxia-response genes such as VEGF.
10
  
Thus, hypoxia upregulates the expression of angiogenic factors, like VEGF 
and the tumor cells export FGF-fibroblast growth factor, VEGF and FGF bind to 
their receptors respectively VEGFR (1-3) and FGFR on the endothelial cells. Both, 
VEGF and FGF activate signal transduction pathways, activating the endothelial 
cells. At this time point the first phase of tumor angiogenesis starts. In the first 
phase, the activation phase, the adventitial cells and pericytes are retracted, while 
the basal membrane of the pre-existing vessels is degraded by proteases, by 
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members of the matrix metalloproteinase family (MMP-9, 12) which are produced 
by the activated endothelial cells.
10, 45 
The basement membrane barrier is disrupted, the endothelial cells, which 
cover the internal wall of a blood vessel, are able to migrate from pre-existing 
vessels towards the angiogenic stimuli and proliferate. The migration of the 
endothelial cells (EC) is based on cell-extracellular interaction that is mediated by 
vascular cell-adhesion molecule, integrin αvβ3 which mediate cell adhesion and play 
an important role in Angiogenesis.
43,44
During the formation phase, the endothelial 
cells, after migrating, are structured into tubes to form capillary-like structures, these 
mature into functional capillaries and then the blood flow is initiated. The formation 
phase is thought to be dependent on E-selectin, which is a transmembrane cell-
adhesion glycoprotein. E-selectin mediates endothelial cell-cell interaction.  
Mesenchymal cells play a decisive role in the formation of mature blood 
vessels. These cells express Angiopoetin-1, which binds to Tie-2 receptors 
expressed on the EC which is thought to help in pericyte recruitment, vessel 
sprouting and vessel stabilization. Tie receptors (Tie-1 and Tie-2) are tyrosine 
kinases and their expression follows VEFGR expression. The ligand for Tie-2 is 
Angiopoetin-1, which upon binding to Tie-2 induces tyrosine phosphorylation of 
Tie-2. Angiopoetin-1 has showed induction of capillary sprouts formation and EC 
survival support. Platelet derived growth factor (PDGF) is excreted by the 
endothelial cell and it functions as a chemoattractant for pericyte precursors, which 
after associating with endothelial cells differentiate into pericytes. The role of 
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pericytes is yet not completely understood, but it is believed that they play a role in 
stabilizing the newly formed blood vessels.
44, 45
 
Angiogenesis is an essential process in progression of malignant tumors due 
to the fact that solid tumors cannot grow beyond 1-2 mm without 
neovascularisation.
46
Various growth factors have proved to stimulate angiogenesis, 
including FGF, transforming growth factor α(TGF α), PDGF and VEGF47. VEGF is 
the most potent angiogenic factor, a glycoprotein with angiogenic, mitogenic and 
vascular permeability enhancing activity in endothelial cells.
48
 
The most widely used method for assessing angiogenesis in conventional 
pathological examination is the determination of microvascular density, due to its 
ease of implementation and its reproducibility. Although it is difficult to measure 
angiogenesis in cancers, the determination of microvascular density and the 
quantification of microvessels stained by immunohistochemistry in histological 
sections is considered to be a reliable indicator of angiogenesis.
49
 
ANGIOGENIC MARKER 
Based on the relationship between angiogenesis and tumour progression, 
various attempts have been made to use microvascular density as a prognostic 
marker in multiple tumour types
50
.The antibodies used in most studies are antibodies 
against factor VIII, antigens CD31 , CD34, and more recently against the CD105 
antigen (endoglin), which are specifically found in the vascular endothelium. 
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CD34 is a heavily glycosylated type I transmembrane molecule, that can be 
phoshorylated by a variety of kinases including Protein kinase C and Tyrosine 
kinases. The classification of epitopes detected by different CD34 monoclonal 
antibodies (MAbs) has aided the selection of appropriate antibodies for use in 
specific clinical and research laboratory settings.  
Detailed structural analyses and cloning studies have confirmed that CD34 is 
a sialomucin, and have suggested that the fine composition of the carbohydrate 
moieties contained in its extended N-terminal region is important in determining its 
interactions with a variety of different ligands.
51
 
CD34 antigen is expressed by varied cell types in the human body. It is 
expressed on small vessel endothelial cells and tumors of epithelial origin.
14,15
 A 
subset of fibroblasts (including embryonic fibroblasts), bone marrow stromal 
progenitors, some cells in fetal and adult nervous tissue, interstitial and adventitial 
fibroblast-like dendritic cells from adult dermis, areolar tissue, fat and somatic and 
visceral collagenous connective tissue express CD34.
52 
 CD34 is also expressed on 
hematopoietic progenitors derived from fetal yolk sac, embryonic liver, and 
extrahepatic embryonic tissues including aorta-associated hematopoietic 
stem/progenitors in the 5-week embryo. 
53, 54 
It is found on several myxoid, fibrovascular, and fibrohistiocytic 
mesenchymal tumors, fatty tumors derived from primitive fibroblast-like dendritic 
cells.
55
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About 40% of acute myeloid leukemias and 65% of pre-B acute 
lymphoblastic leukemias express the CD34 molecule, whereas only 1-5% of acute 
T-lymphoid leukemias express the CD34 antigen. CD34 is often expressed on blasts 
from chronic myeloid leukemia patients in blast crisis; whereas chronic phase cells, 
other chronic leukemias and lymphomasof more differentiated phenotypes are 
uniformly negative.
56, 57 
Liver tissue sections obtained by biopsy from 56 patients with HCV-
associated chronic liver diseases were examined immunohistochemically using anti-
CD34, anti–von Willebrand factor (vWF), and anti–vascular endothelial growth 
factor (VEGF) antibodies. CD34 was stained in the sinusoid, showing dotty, linear, 
semicircular, or circular patterns. They concluded that CD34 could be recognized as 
an independently significant factor for development of HCC and CD34-positive 
endothelial cells are regulated by several factors, such as VEGF and might play a 
substantial role in hepatocarcinogenesis.
58
 
 A prospective study was done to evaluate the correlation of tumor 
microvessel density (MVD) with clinicopathologic features and postoperative 
recurrence in patients undergoing resection of hepatocellular carcinoma (HCC). 
Tumor MVD was assessed in 100 patients with resection of HCC using a computer 
image analyzer after immunostaining for CD34 (MVD-CD34) and von Willebrand 
factor (MVD-vWF), respectively. They concluded that (1) CD34 seems to be a 
better endothelial marker than vWF for the study of MVD in HCC; (2) a high MVD-
CD34 is predictive of early recurrence after resection of HCCs.
59
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A study was done with formalin-fixed, paraffin-embedded sections of oral 
lymphangiomas (5 cases), oral hemangiomas (5 cases) and oral squamous cell 
carcinomas (OSCC, 20cases) which were double immunostained with anti-CD34 
and D2-40 monoclonal antibodies using ENVISION-polymer technique.  
The results showed that D2-40 positivity was detected in all lymphatics, 
while all blood vessels were positive for CD34 in oral neoplastic lesions. These 
results showed that D2-40 MoAb is a powerful and a specific marker for lymphatics 
that can be used to confirm the localization of lymphatics in OSCC. Moreover, 
CD34&D2-40 double staining is a reliable IHC method by which blood and 
lymphatic vessels can be observed simultaneously in the same section.
16
 
A study was done to examine relationship between microvessel density as a 
parameter of tumour angiogenesis measured by immunohistochemical expression of 
CD34 and the grade of non Hodgkins Lymphoma (histological malignancy as 
determined by REAL classification). 40 lymph node samples of patients with newly 
diagnosed nHL (17 women, 23 men; aged 48-70 yrs, median age 64 yrs; stage III 
and IV) and treated at the Department of Haematology, Wrocław Medical 
University in 1999-2002 were used in the study . Statistical analysis of microvessel 
staining demonstrated no correlation between tumor MVD and grade of histological 
malignancy in lymph nodes of nHL patients. Nevertheless, angiogenesis observed in 
nHL provides rationale for use of angiogenesis inhibitors in lymphoma therapy.
60
 
 A study was conducted in 42 cases of human OSCC and 10 specimens of 
normal oral mucosa to investigate the correlation between the expression of tissue 
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factor and the microvessel density in OSCC so as to observe the function of tissue 
factor in angiogenesis, provide valuable scientific basis for the research and 
treatment of OSCC. Tumor microvessel density was evaluated using anti-CD34 
antibody as endothelial marker. The study concluded that tissue factor expression 
had positive correlation with MVD in OSCC. Tissue factor takes part in the 
angiogenesis of OSCC and may act in growth, invasion and metastasis of OSCC.
 61
 
Analysis was done on MVD immunohistochemically (mouse monoclonal 
anti-human CD34) in 49 paraffin- embedded specimens, 35 OSCCs, 9 leukoplakias 
and 5 normal oral tissues. Mast cell density (MCD) was associated with MVD, 
toluidine blue counterstaining revealed mast cells. They concluded that there was 
increase in MVD with increase in MCD proving that mast cells are attracted at the 
lesion site and may turn on an angiogenic switch during tumorigenesis in OSCC.
62
 
A study was conducted with 84 OSCC specimens for immunohistochemical 
staining for three common endothelial makers: von Willebrand factor (vWF), CD31 
and CD34. They concluded that tumor angiogenesis and the density of newly 
formed vessels are of potential prognostic relevance in the assessment of malignant 
neoplasia. The endothelial marker CD34 was better in the assessment of tumor 
vascularization of OSCCs.
63
 
The vascular bed of 29 solar keratoses, 30 superficially invasive squamous 
cell carcinomas and 30 invasive squamous cell carcinomas were studied. The 
microvascular area was quantified by comparing panendothelial (CD34) with 
neoangiogenesis (CD105) immunohistochemical markers. The result showed 
40 
 
increase in MVD staining with both CD105 and CD34. They concluded that 
angiogenic switch occurs early in the development of cutaneous squamous cell 
carcinoma and the rate of neovascularization is parallel to tumor progression. This 
study demonstrated the dependence of skin carcinogenesis on angiogenesis.
64 
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The study consisted of 35 patients (n= 35) in which Group 1 was 10 
metastasizing OSCC, Group 2 was 15 non metastasizing OSCC and Group 3 was 10 
normal. The age range in each group (Graph 1) was as follows: in Group 1, 37.5% 
were within 41to 50 years and 50% were within 61 to 80 years. In Group 2, 23% 
were within 20 to 40years, 62.5% were within 41 to 60 years and 50% were within 
61 to 80 years. In Group 3 76.9% were within 20 to 4years. 
 Gender distribution in the study population was: 68.6% males and 31.4% 
females. The gender within the study groups was statistical: Group 1, 50% males 
and 27.3% females. In Group 2, 50% were males and 27.3% were females. In Group 
3, 16.7%were males and 54.5% were females (Graph 2). The p value 0.71 showed 
that there was no statistically significant relation between gender and the study 
groups. 
 Histopathologic grading in the study population (Graph 3) in Group 
1(n=10) 40 % (n=4) were well differentiated OSCC, 50% (n=5) were moderately 
differentiated OSCC and 10% (n=1) were poorly differentiated OSCC. In Group 2, 
86.6% (n=13) were well differentiated, 6.7% (n=1) were moderately differentiated 
and 6.7% (n=1) were poorly differentiated OSCC. CD 34 staining was 100% 
positive for Group 1, 100% positive for Group 2 and 90% positive for Group 
3(Graph 4). 
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Comparison of number of CD 34 positive blood vessels /mm
2
 of the tissue 
section between Group 2 and Group 3 (Table 1) 
This data showed that there is no statistical significance on comparing the 
normal and the non metastatic OSCC group. The mean number of vessels per mm
2 
in Group 2 (Range: 2.37 to 12.67) was 6.22 (S.D= 3.21) and in Group 3 (Range:0 to 
13.58) with a mean of 5.85 and(S.D=4.71). 
 
Comparison of number of CD 34 positive blood vessels/mm
2 
of the tissue section 
between the Group 1 and Group 3 (Table 2) 
The comparison revealed that there is significance on comparing the normal 
and the metastatic OSCC group (p=0.003). The mean number of vessels per mm
2 
in 
Group 1(Range: 6.98 to 17.04) was 12.88 ± 3.24 and in Group 3 (Range:0 to 13.58) 
with a mean of 5.85 ± 4.71. 
 
Comparison of number of CD 34 positive blood vessels/mm
2
 of the tissue 
section between the Group 1 and Group 2 (Table 3) 
The comparison revealed that there is statistical significance on comparing 
the non metastatic and the metastatic OSCC group (p=0.000). The mean number of 
vessels per mm
2 
in group 2(Range: 2.37 to 12.67) was 6.22 ± 3.21 and in group 1 
(Range:0.97 to 17.04) with a mean of 12.88 ± 3.24. 
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Comparison of number of CD 34 positive blood vessels/mm
2 
of the tissue section
 
between the three study groups (Table 4) 
On comparison of the number of blood vessels per square millimeter among 
the different study groups, it was observed that there was a statistically significant 
difference between the groups (p=.001). In Group 1 mean was 12.88 ± 3.24, in 
Group 2 the mean was 6.22 ± 3.21 and in Group 3 the mean was 5.84 ± 4.71. 
 
Comparison of intensity of blood vessels between the study groups (Table 5) 
On evaluating the intensity of staining in the study groups, in Group 1, 20% 
(n=1) cases showed mild intensity and 80% (n=8) cases showed moderate intensity. 
In Group 2, 86.7% (n=13) cases showed mild intensity and 13.3% (n=2) showed 
moderate intensity and in Group 3 50% (n=5) cases showed mild intensity, 40% 
(n=4) showed moderate intensity and 10% (n=1) cases showed absence of stain. The 
comparison was considered to be statistically significant (p=0.007). 
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Graph 1 
Distribution of age within the study groups 
 
Graph 2 
Distribution of gender within the study groups 
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Graph 3 
Distribution of histopathologic grading between non metastatic  
and metastatic OSCC groups 
 
Graph 4 
CD 34 positivity among study groups 
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Graph 5 
Distribution of staining intensity among the groups 
 
Table 1 
Comparison of CD 34 positive vessels/mm
2
 between  
Group 3 and Group 1 
 
Group N Mean S.D 
Min 
Value 
Max 
Value 
Mean 
rank 
p Value 
Group 3 10 5.84 4.71 0 13.58 6.6  
0.003* Group 1 10 12.88 3.24 6.97 17.04 14.4 
Total  20 9.36 5.34 0 17.04  
*p value < 0.05 was considered to be statistically significant 
 (p value was derived using Mann Whitney U Test) 
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Table 2 
Comparison of CD 34 positive vessels between  
Group 1 and Group 2 
Group N Mean S.D 
Min 
Value 
Max 
Value 
Mean 
rank 
p Value 
Group 2 15 6.22 3.21 2.37 12.67 8.57  
0.000* Group 1 10 12.88 3.24 6.97 17.04 19.65 
Total  25 8.85 4.62 2.37 17.04  
*p value < 0.05 was considered to be statistically significant 
 (p value was derived using Mann Whitney U Test) 
 
Table 3 
Comparison of CD 34 positive vessels/mm
2
 between  
Group 3 and Group 2 
 
Group N Mean S.D 
Min 
Value 
Max 
Value 
Mean 
rank 
p Value 
Group 3 10 5.84 4.71 0 13.58 13  
1.000 
Group 2 15 6.22 3.21 2.37 12.67 13 
Total  25 6.03 3.8 0 13.58  
(p value was derived using Mann Whitney U Test) 
  
Group 1-metastatic OSCC 
Group 2-non metastatic OSCC 
Group 3-control 
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Table 4 
Comparison of blood vessels/mm
2
 between the study groups 
Group N Mean S.D 
Min 
Value 
Max 
Value 
Mean 
rank 
p Value 
Group 1 10 12.88 3.24 6.97 17.04 28.55  
 
0.001* 
Group 2 15 6.22 3.21 2.37 12.67 13.57 
Group 3 10 5.84 4.71 0 13.58 14.10 
Total 25 8.85 4.62 2.37 17.04  
*p value < 0.05 was considered to be statistically significant 
 (p value was derived using Krusskal Wallis Test) 
Table 5 
Distribution of staining positivity among the groups 
Intensity 
Group 3 
(10) 
Group 2 
(15) 
Group 1 
(10) p value 
N % N % N % 
Absence 2 20 0 0 0 0 
0.007* Mild 4 40 13 86.7 2 20 
Moderate 4 40 2 13.3 8 80 
*p value < 0.05 was considered to be statistically significant 
  
Group 1-metastatic OSCC 
Group 2-non metastatic OSCC 
Group 3-control 
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Fig. 1 
 
Reagents Used 
Fig. 2 
 
Antibodies used 
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Fig. 3 
 
 
 
CD34 positivity in normal buccal mucosal tissue 
 
Fig. 4 
 
Increased vasculature in the peritumoral area 
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Fig. 5A 
 
CD34 positivity in non metastatic OSCC 
Fig. 5B 
 
CD34 positivity in non metastatic OSCC 
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Fig. 6A 
 
CD 34 positivity in metastatic OSCC 
Fig. 6B  
                  
CD 34 positivity in metastatic OSCC 
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Several studies indicate that angiogenesis has a central role in the 
pathogenesis and progression of malignant disease, directly affecting the ability of 
the tumor to grow, invade, and eventually metastasize
65
. Studies in oral squamous 
cell carcinoma patients have shown that vascularity increases from normal mucosa 
to moderate dysplasia to carcinoma
66-71
. In accordance with this view, in our study 
we used CD 34, a vascular endothelial cell membrane marker to determine the micro 
vascular density which reflects tumor angiogenesis. 
The most widely used method was introduced by Weidner et al
72
in which the 
number of microvessels counted on the histological sections of the tumor gave the 
MVD (microvascular density) and this served as an indicator of the angiogenic 
potential of the tumor. In our study, we counted the number of vessels in histological 
sections of metastatic and non metastatic tumor tissues stained with monoclonal 
antibody anti-CD 34 which stains both the blood and the lymphatic vessels. In most 
of the studies monoclonal antibody anti-CD31 has been used to assess tumor 
angiogenesis. However, it is not widely used now due to false positivity as it cross 
reacts with plasma cells present in intratumoral inflammatory infiltrate.
73
 
Our study consisted of 35 subjects divided into 3 Groups, Group 1 consisted 
of metastatic OSCC cases (n=10), Group 2 comprised of non metastatic OSCC cases 
(n=15) and Group 3 is the control (n=10). The mean age of the patients with non 
metastatic oral OSCC was 57.46 ± 14.88 years and metastatic OSCC was 62.5 
±12.93 years.  This is similar to that of Ascani et al,
74
 in which the mean age was 
66.6 years among the OSCC group. 
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 In our study groups 37.5% were within age 41 to 60 years in Group 1 and 
62.5% were within age 41 to 60 years in Group 2, 50% were within 61 to 80 yrs in 
Group 1 and Group 2, similar to a study conducted by Sharma P et al
75
 in which they 
concluded that the largest number of OSCC developed in 4
th
 and 5
th
 decade.  
OSCC in our study was seen after the fourth decade except for Group 2 in 
which 23% were below 40 yrs. Although OSCC is a disease of older age and aging 
is a factor that increases the risk of its occurrence, 8.7% of the cases were seen in 
patients under 40 years and as shown in other studies, although in small numbers. 
Young patients presenting with OSCC have been increasingly noted worldwide 
since the 1990s and some studies have shown an increase of these cases only in 
specific oral sites
5.
 
Among the OSCC patients (n=25) included in our study including metastatic 
and non metastatic OSCC  the number of males were greater than females, similar to 
a retrospective study done by Sharma P et al
75
 in which male: female proportions of 
OSCC was 2.2:1.  
CD 34 staining showed 100% positivity in metastatic and non metastatic 
OSCC whereas it showed 90% positivity in control group (Fig. 3). This was similar 
to the study done by Xuan et al
16
 and Shu- hui et al
63
 which proved that CD 34 
specifically stained the endothelial cells of blood vessels. Well differentiated OSCC 
consisted of 86.6% of the total number of OSCCs in our study population. The 
absence of staining in one of the cases in the control group was due to inadequate 
size of the tissue specimen and scant connective tissue. 
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There was a high statistical significance (p=0.000) on comparing the number 
of blood vessels/mm
2 
(microvascular density) between non metastatic OSCC and 
metastatic OSCC groups.  The microvascular density was increased in metastatic 
OSCC. This is similar to the study done by Ascani et al
72
 with 64 oral squamous cell 
carcinoma patients wherein the mean microvascular density in patients with non 
metastatic OSCC was significantly less than metastatic OSCC (p=.0001). Increased 
MVD correlated with higher score of lymph node involvement as studied by 
Mayumi et al.
76
 
On comparing the non metastatic OSCC (Fig 5A, 5B) and metastatic OSCC 
group, the latter showed increased vessel density with a statistical significance of   
(p=0.000).   
The staining intensity of the blood vessels in controls when compared with 
non metastatic OSCC showed no statistical significance (p=1).The intensity of blood 
vessels of metastatic OSCC was higher when compared with that of normal oral 
epithelium and non metastatic OSCC with a high statistical significance of p=0.003 
and p=0.000 respectively(Fig.6A, 6B). 
We observed an increased micro vascular density in the peritumoral region 
when comparing the intratumoral region, this observation was similar to that of 
Margaritescu et al
77
 in which the density of vessels were more in the advancing 
tumor front than the interior of the tumor (Fig.4). 
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On comparing the micro vascular density between control and non metastatic 
OSCC, there was no statistical significance which may probably be due to the 
hypoxia phenomenon. Hypoxia is one of the most important factors which induce 
angiogenesis thereby facilitating tumor progression. Hypoxia causes increase 
expression of HIF (hypoxia inducing factor) which in turn stimulates angiogenesis. 
There is evidence that tumors that lack access to blood vessels will not grow more 
than 4mm in vitro and up to 2mm in vivo.
78
  
Though there was an absence of statistically significant correlation between 
the two groups, the actual numbers revealed an increased number of vessels per unit 
area of the tissue in non metastasizing OSCC (Annexure2). The control tissue may 
not have been subject to hypoxic conditions when compared to metastatic OSCC. 
The increased micro vascular density in metastatic OSCC when compared  to 
non metastatic OSCC is probably due to the variations in the angiogenic 
characteristics of the metastasizing clones and imbalance between local or systemic 
stimulators and inhibitors of angiogenesis, this could account for the different levels 
of neovascularization in primary and metastatic tumors.
79 
Pazouki et al 
80
 in his study showed that there was an increase in vascularity 
of tissues, as it transformed from normal to dysplasia and finally to carcinoma. This 
supports the importance of angiogenesis for tumor progression in oral squamous cell 
carcinoma.  
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There was no relevant history of habits and their duration for most of the 
subjects in the study. There were only 2 cases of poorly differentiated OSCC. As CD 
34 stains the endothelial cells of blood and lymph vessels, a more specific antibody 
for the endothelium of the blood vessel will probably more closely reflect the role of 
angiogenesis in metastasis of tumor. 
There was a statically significant difference between all the 3 groups with 
respect to microvascular density. There was increased microvascular density in 
cancer compared to normal however; this difference reached statistical significance 
when the non metastatic group was compared with metastatic group. These findings 
are similar to those reported by other investigators such as Folkman et al
81
 who have 
shown a strong correlation between tumor growth and vascularity. Our findings 
indicate that microvascular density has the potential to be used as a factor to 
determine prognosis in oral squamous cell carcinoma. 
Folkman et al 
81
 were responsible for the pioneering studies proving a 
correlation between tumor growth and vascular density. Numerous studies have 
shown a positive correlation between micro vascular density and prognosis of oral 
squamous cell carcinoma demonstrating that high microvascular density is related to 
metastatic potential of tumor 
82-84
.  
In agreement with these results, our study also showed that there is 
statistically significant increase in microvascular density in metastasizing oral 
squamous cell carcinoma when compared to non metastasizing oral squamous cell 
carcinoma (p=0.000). Therefore, microvascular density should be considered as one 
of the independent prognostic factor for oral squamous cell carcinoma. 
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Tumors require blood supply for their growth and dissemination. 
Angiogenesis is a complex process and there is evidence that it is closely linked to 
cell proliferation and apoptosis, thus representing a critical step for tumor formation 
and progression. It is a well accepted paradigm that tumors recruit new blood vessels 
from the existing circulation (angiogenesis) and participates in tumor invasion and 
metastases. The number of vessels per unit area of tumor tissue is denoted by 
microvascular density. 
This immunohistochemical study comprised of a total of 35 subjects in three 
groups: ten metastatic OSCC (Group 1), fifteen non metastatic OSCC (Group 2) and 
ten control group (Group 3). CD 34 antibody against vascular endothelial cells was 
used to study the microvascular density between the three groups. 
The conclusions from the study are: 
 CD 34 positivity is observed in the endothelial cells of blood vessels and 
lymphatic vessels.  
 There is no difference in microvascular density between the control group 
and the non metastatic OSCC group. (p=1) 
 Microvascular density is higher in the metastatic OSCC group when 
compared to the normal group (p=0.003) 
 Microvascular density is higher in the metastatic OSCC group when 
compared to the non metastatic OSCC (p=0.000) 
 Microvascular density is higher in the peritumoral areas than in the 
intratumoral areas. 
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Our results indicate that CD 34 is a potential marker to predict OSCC 
invasiveness and metastasis and staining with CD 34 may be useful in determining 
the prognosis of OSCC.  
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Annexure 2 – Lymphatic vessel density in the cases studied 
Case No Vessels/mm2 Number of grids counted 
Group1 
S-102 13.143 7 
S-268 12 3 
S-1332 6.967 31 
S-650 14.944 18 
S-213 8.373 27 
S-153 13.429 28 
S-1065 16.81 79 
S-1035 17.042 24 
4225/11-C 13.713 23 
S-703 12.364 44 
Group 2 
4071/11 11.8 12 
4232/11 4.22 14 
4265/11 12 30 
4231/11 2.366 19 
4163/11-B 3.583 40 
3966/11 4.055 18 
4270/11 12.666 4 
4229/11 46.12 26 
S-653 5.615 34 
S-1021 5.8 36 
S-097 4.972 25 
S-256 5.301 18 
S-4137 5.711 27 
S-315 5.32 40 
4227/11 4.321 14 
Group 3 
4054/11 12.09 11 
4055/11 0 6 
4056/11 5.888 8 
4057/11 0.777 7 
4058/11 13.58 12 
4059/11 6.923 10 
4468/11 5.4 13 
4469/11 1.22 5 
4445/11 9.214 8 
4463/11 3.285 9 
  
